No Data
No Data
Xianjian Technology disclosed a “fake” financial report. The slight decline in performance was an indication. Overseas revenue increased by 30% and subsidiary valuations increased 1.7 times
① Xianjian Technology achieved revenue of 1,267 billion yuan in 2023, an increase of 15.5% year on year; net profit after deducting non-return to mother was 423 million yuan, a slight decrease of 2.3% year on year; ② The valuation of the subsidiary Yuanxin Technology after Series B financing increased sharply by 173%, and the fair value of its redeemable shares increased significantly accordingly.
Lifetech Scientific Books Lower 2023 Profit Despite Surge in Revenue
Lifetech Scientific (HKG:1302) posted a net profit attributable to owners of about 263.2 million yuan for the year ended Dec. 31, 2023, down from 325.3 million yuan in the previous year, according to
Xianjian Technology Announces 2023 Annual Results: Strong International Business Growth, Steady Development Driven by Innovation
SHENZHEN, March 28, 2024/PRNewswire/ -- On March 28, 2024, Xianjian Technology (“the Company” or “Xianjian Technology”, stock code: 1302.HK) and its subsidiaries (collectively, the “Group”) announced audited comprehensive results for the year ended December 31, 2023 (“during the reporting period”): Strong international business growth: The Group achieved sales revenue of approximately RMB 1,267.2 million, an increase of about 15.5% year on year, including overseas markets Sales increased significantly year over year by approximately 3
Xianjian Technology (01302) announced annual results. Profit attributable to shareholders of 263 million yuan decreased by 19.09% year-on-year
According to the Zhitong Finance App, Xianjian Technology (01302) announced the results for the year ended December 31, 2023. The group obtained revenue of RMB 1,267 billion (same unit), an increase of 15.48% over the previous year; profit attributable to the company owners was 263 million yuan, a decrease of 19.09% over the previous year; and the basic profit per share was 6 points. According to the announcement, the increase in revenue was mainly due to increased revenue from sales of congenital heart disease occulators and laminated stents.
LIFETECH SCI: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
LifeTech Scientific Flags Significant Profit Drop in 2023
LifeTech Scientific (HKG:1302) expects to record a "significant" decline in net profit for the year ended December 2023 when compared to 2022, according to a Friday filing with the Hong Kong bourse. T
No Data